Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone781-345-9001
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$89.79 million
Profitability
Miscellaneous
Employees262
Next Earnings Date2/5/2020 (Estimated)
OptionableNot Optionable
ConforMIS (NASDAQ:CFMS) Frequently Asked Questions
What is ConforMIS's stock symbol?
ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."
How were ConforMIS's earnings last quarter?
ConforMIS Inc (NASDAQ:CFMS) announced its quarterly earnings results on Wednesday, October, 30th. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical instruments supplier earned $17.30 million during the quarter, compared to the consensus estimate of $17.80 million. ConforMIS had a negative net margin of 41.36% and a negative return on equity of 115.71%. View ConforMIS's Earnings History.
When is ConforMIS's next earnings date?
What price target have analysts set for CFMS?
2 brokers have issued 1 year target prices for ConforMIS's stock. Their forecasts range from $3.00 to $4.00. On average, they expect ConforMIS's share price to reach $3.50 in the next year. This suggests a possible upside of 86.2% from the stock's current price. View Analyst Price Targets for ConforMIS.
What is the consensus analysts' recommendation for ConforMIS?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.
What are Wall Street analysts saying about ConforMIS stock?
Here are some recent quotes from research analysts about ConforMIS stock:
- 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (11/4/2019)
- 2. BTIG Research analysts commented, "$3 PT on Improving Trends We maintain our Buy rating and $3 PT following 1Q19 results which came in slightly ahead of expectations. Revenue of $20.6M compared favorably to BTIG/Street estimates of $20.0M/$20.1M. Noticeably CFMS saw encouraging uptake with both iTotal PS (+29% xFx) and iTotal Hip (still in the early stages of launch). GMs continued their upward trajectory, increasing 290 bps Y/Y to 47.6%. We believe CFMS’s worst days are behind it and the company is entering into a phase of improved and steady LSD growth driven by existing and recently launched products which give a growing distributor base a full recon line to sell. Recon surgery is clearly moving rapidly towards robotics but CFMS is going against the grain with an alternative option that may appeal to a group of surgeons who don’t want to be tied to a robotic system." (5/2/2019)
Has ConforMIS been receiving favorable news coverage?
Headlines about CFMS stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ConforMIS earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for ConforMIS.
Are investors shorting ConforMIS?
ConforMIS saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,570,000 shares, an increase of 23.2% from the September 30th total of 3,710,000 shares. Based on an average trading volume of 857,200 shares, the days-to-cover ratio is currently 5.3 days. Currently, 7.1% of the shares of the company are sold short. View ConforMIS's Current Options Chain.
Who are some of ConforMIS's key competitors?
Some companies that are related to ConforMIS include Establishment Labs (ESTA), Sientra (SIEN), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), Histogenics (HSGX), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN), Precision Therapeutics (POAI), NanoVibronix (NAOV), Wound Management Technologies (WNDM), Bionik Laboratories (BNKL), Allied Healthcare Products (AHPI), Ocugen (OCGN) and Avitar (AVTI).
What other stocks do shareholders of ConforMIS own?
Who are ConforMIS's key executives?
ConforMIS's management team includes the folowing people:
- Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
- Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
- Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
- Mr. Ed Kilgallen, VP of Operations
- Ms. Lisa M. Donnelly, Sr. VP of Global Marketing
When did ConforMIS IPO?
(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
Who are ConforMIS's major shareholders?
ConforMIS's stock is owned by a variety of of institutional and retail investors. Top institutional investors include CAPROCK Group Inc. (0.29%), Gabelli Funds LLC (0.20%), Creative Planning (0.18%), Russell Investments Group Ltd. (0.05%) and Teton Advisors Inc. (0.02%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.
Which major investors are buying ConforMIS stock?
CFMS stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning, CAPROCK Group Inc., Russell Investments Group Ltd., Gabelli Funds LLC and Teton Advisors Inc.. View Insider Buying and Selling for ConforMIS.
How do I buy shares of ConforMIS?
Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ConforMIS's stock price today?
One share of CFMS stock can currently be purchased for approximately $1.88.
How big of a company is ConforMIS?
ConforMIS has a market capitalization of $129.18 million and generates $89.79 million in revenue each year. The medical instruments supplier earns $-43,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. ConforMIS employs 262 workers across the globe.View Additional Information About ConforMIS.
What is ConforMIS's official website?
How can I contact ConforMIS?
ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]
MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
